AR104721A1 - Fragmento fab anti-ngf humano - Google Patents

Fragmento fab anti-ngf humano

Info

Publication number
AR104721A1
AR104721A1 ARP160101483A ARP160101483A AR104721A1 AR 104721 A1 AR104721 A1 AR 104721A1 AR P160101483 A ARP160101483 A AR P160101483A AR P160101483 A ARP160101483 A AR P160101483A AR 104721 A1 AR104721 A1 AR 104721A1
Authority
AR
Argentina
Prior art keywords
human fab
seq
amino acid
acid sequence
pharmaceutical composition
Prior art date
Application number
ARP160101483A
Other languages
English (en)
Inventor
Aoki Toshiaki
Fujita Hirotada
Tanaka Hirotsugu
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR104721A1 publication Critical patent/AR104721A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se provee un fragmento de anticuerpo Fab anti-NGF humano superior, que conservara una actividad de neutralización elevada, que presentara menos efectos secundarios como resultado de una exposición sistémica y que pudiera ejercer un efecto farmacológico local. El objetivo se logra mediante un fragmento de anticuerpo Fab-anti-NGF humano que comprende un fragmento de la cadena pesada que consiste en la secuencia de aminoácidos que se representa en SEQ ID Nº 5 y una cadena liviana que consiste en la secuencia de aminoácidos que se representa en SEQ ID Nº 8. Reivindicación 12: La composición farmacéutica de acuerdo con la reivindicación 11, caracterizada porque es una composición farmacéutica que puede ser administrada de manera local para tratar el dolor postoperatorio.
ARP160101483A 2015-05-22 2016-05-20 Fragmento fab anti-ngf humano AR104721A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015104806 2015-05-22

Publications (1)

Publication Number Publication Date
AR104721A1 true AR104721A1 (es) 2017-08-09

Family

ID=57393503

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101483A AR104721A1 (es) 2015-05-22 2016-05-20 Fragmento fab anti-ngf humano

Country Status (22)

Country Link
US (1) US11260124B2 (es)
EP (1) EP3299461B1 (es)
JP (1) JP6700620B2 (es)
KR (1) KR102440054B1 (es)
CN (1) CN107614683B (es)
AR (1) AR104721A1 (es)
AU (1) AU2016268625B2 (es)
BR (1) BR112017025029A2 (es)
CA (1) CA2986210C (es)
CO (1) CO2017012397A2 (es)
HK (1) HK1246349A1 (es)
IL (1) IL255832B (es)
MA (1) MA42138A (es)
MX (1) MX2017014911A (es)
MY (1) MY184164A (es)
PH (1) PH12017502126A1 (es)
RU (1) RU2729825C2 (es)
SG (1) SG11201709589XA (es)
TW (1) TWI706959B (es)
UA (1) UA123209C2 (es)
WO (1) WO2016190263A1 (es)
ZA (1) ZA201708169B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10725059B2 (en) * 2015-04-06 2020-07-28 Meso Scale Technologies, Llc. High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus
NL2017890B1 (nl) * 2016-11-29 2018-06-11 Josh Ip Iii B V Medische transportinrichting, hulpaandrijving, en werkwijze voor het transporteren van een dergelijke transportinrichting
US20210147529A1 (en) * 2018-05-15 2021-05-20 Astellas Pharma Inc. Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527358A (en) 1994-01-21 1996-06-18 Medtronic, Inc. Temporary medical electrical lead
WO2004032852A2 (en) 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
PL215171B1 (pl) 2002-12-24 2013-10-31 Rinat Neuroscience Corp Przeciwcialo przeciw czynnikowi wzrostu nerwów (NGF) lub jego fragment, kompozycja farmaceutyczna, zestaw, sposób wytwarzania przeciwciala lub jego fragmentu, zastosowanie skutecznej ilosci antagonistycznego przeciwciala anty-NGF lub jego fragmentu, zastosowanie antagonistycznego przeciwciala anty-NGF lub jego fragmentu, izolowany polinukleotyd zawierajacy sekwencje nukleotydowa kodujaca przeciwcialo lub jego fragment, wektor oraz komórka gospodarza zawierajaca polinukleotyd
TWI385180B (zh) 2003-07-15 2013-02-11 Amgen Inc 作為選擇性神經生長因子(ngf)通道抑制劑之人類抗-ngf中和抗體
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CA2562024C (en) * 2004-04-07 2014-05-27 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ES2435691T3 (es) 2005-01-24 2013-12-23 Medimmune Limited Anticuerpos humanos contra NGF humano
US9532943B2 (en) 2010-12-20 2017-01-03 Cormatrix Cardiovascular, Inc. Drug eluting patch for the treatment of localized tissue disease or defect
JP2007244601A (ja) 2006-03-15 2007-09-27 Kanazawa Univ 心筋用パッド
EP2572729A3 (en) 2007-08-10 2013-06-05 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
SG10201703707YA (en) * 2009-03-19 2017-06-29 Chugai Pharmaceutical Co Ltd Pharmaceutical formulation containing improved antibody molecules
PE20121540A1 (es) 2009-05-04 2012-12-22 Abbott Res Bv Anticuerpos contra el factor de crecimiento nervioso (ngf) con estabilidad in vivo mejorada
BR112013015308A2 (pt) 2010-12-20 2016-09-20 Cormatrix Cardiovascular Inc dispositivo para administrar um inibidor de hmg coa reductase ao tecido cardiovascular para tratar uma doença cardiovascular
EP3498732B1 (en) * 2011-05-06 2021-11-17 Zoetis Services LLC Anti-nerve growth factor antibodies and methods of preparing and using the same
EP3502136A1 (en) * 2011-05-06 2019-06-26 Nexvet Australia Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
DK2743348T3 (en) * 2011-08-11 2018-02-26 Astellas Pharma Inc Hitherto UNKNOWN ANTI-HUMAN NGF ANTIBODY
PE20150212A1 (es) 2012-06-08 2015-02-27 Glenmark Pharmaceuticals Sa Anticuerpos anti-trka con propiedades inhibitorias mejoradas y sus derivados
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトngf抗体
US9127055B2 (en) * 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
AU2015362775B2 (en) 2014-12-17 2019-07-04 Dow Global Technologies Llc Viscoelastic polyurethane foam with aqueous polymer dispersion

Also Published As

Publication number Publication date
JPWO2016190263A1 (ja) 2018-04-12
RU2017145071A (ru) 2019-06-24
TW201713691A (zh) 2017-04-16
CA2986210C (en) 2022-04-26
ZA201708169B (en) 2019-06-26
CN107614683B (zh) 2020-12-22
HK1246349A1 (zh) 2018-09-07
MX2017014911A (es) 2018-03-23
UA123209C2 (uk) 2021-03-03
IL255832B (en) 2021-07-29
IL255832A (en) 2018-01-31
AU2016268625A1 (en) 2017-12-07
KR102440054B1 (ko) 2022-09-06
US11260124B2 (en) 2022-03-01
EP3299461A1 (en) 2018-03-28
EP3299461B1 (en) 2023-03-29
MA42138A (fr) 2018-03-28
AU2016268625B2 (en) 2022-01-27
CA2986210A1 (en) 2016-12-01
KR20180006391A (ko) 2018-01-17
US20180147281A1 (en) 2018-05-31
RU2017145071A3 (es) 2019-10-17
SG11201709589XA (en) 2017-12-28
CN107614683A (zh) 2018-01-19
MY184164A (en) 2021-03-24
WO2016190263A1 (ja) 2016-12-01
CO2017012397A2 (es) 2018-02-28
BR112017025029A2 (pt) 2018-08-07
TWI706959B (zh) 2020-10-11
PH12017502126A1 (en) 2018-05-07
RU2729825C2 (ru) 2020-08-12
EP3299461A4 (en) 2018-12-19
JP6700620B2 (ja) 2020-05-27

Similar Documents

Publication Publication Date Title
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
ECSP21086530A (es) Derivados de ácido itacónico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable
AR107014A1 (es) Formulación farmacéutica acuosa
CL2016000530A1 (es) Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).
BR112017023269A2 (pt) métodos para tratamento de câncer
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
PE20161390A1 (es) Anticuerpos multiespecificos
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
DOP2017000035A (es) Inhibidores de la proteina quinasa c y metodos de su uso
EA201791518A1 (ru) Способы лечения заболеваний сетчатки
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
CO2019003865A2 (es) Proteína terapéutica
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
AR104721A1 (es) Fragmento fab anti-ngf humano
CO6280488A2 (es) Combinacion farmaceutica
AR109799A1 (es) Composición para el tratamiento del cabello
AR108790A1 (es) Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
CY1122708T1 (el) Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение